Latest Glycan Stories

WASHINGTON, Jan. 28, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today reinforced its commitment to advancing biotherapeutic characterization technology at the Well Characterized Biotechnology Pharmaceuticals 2013 Symposium (WCBP 2013). More specifically, Waters(®) today introduced an expansion of its Biopharmaceutical Platform Solution with UNIFI(®), new ACQUITY UltraPerformance LC(®) (UPLC(®)) CSH130 C(18) and XSelect(TM) HPLC CSH130 C(18) columns for peptide...

As a step toward designing the first effective vaccine against HIV, the virus that causes AIDS, scientists are reporting new insights into how a family of rare, highly potent antibodies bind to HIV and neutralize it — stop it from infecting human cells. The antibodies were isolated from people infected with HIV and work against a wide range of HIV strains. The researchers described the study today at the 244th National Meeting & Exposition of the American Chemical Society, the world's...

Technique will help scientists understand how cells' common sugar molecules influence inflammation, cancer metastasis, and related conditions Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body. The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for...

Whether you become infected by some strains of rotavirus may depend on your blood type. Some strains of rotavirus find their way into the cells of the gastrointestinal tract by recognizing antigens associated with the type A blood group, a finding that represents a new paradigm in understanding how this gut pathogen infects humans, said Baylor College of Medicine researchers in an online report in the journal Nature. Intestinal pathogen Rotavirus is a major intestinal pathogen that...

Whether you become infected by some strains of rotavirus may depend on your blood type. Some strains of rotavirus find their way into the cells of the gastrointestinal tract by recognizing antigens associated with the type A blood group, a finding that represents a new paradigm in understanding how this gut pathogen infects humans, said Baylor College of Medicine researchers in an online report in the journal Nature. Rotavirus is a major intestinal pathogen that is the leading cause of...

The traditional way of making medicines from ingredients mixed together in a factory may be joined by a new approach in which doctors administer the ingredients for a medicine separately to patients, and the ingredients combine to produce the medicine inside patients' bodies. That's one promise from an emerging new field of chemistry, according to the scientist who founded it barely a decade ago. Carolyn Bertozzi, Ph.D., spoke on the topic — bioorthogonal chemistry — here today in...

Escherichia coli – a bacteria considered the food safety bane of restaurateurs, grocers and consumers – is a friend. Cornell University biomolecular engineers have learned to use E. coli to produce sugar-modified proteins for making pharmaceuticals cheaper and faster. (Nature Chemical Biology, March 25, 2012.) Matthew DeLisa, Cornell associate professor of chemical and biomolecular engineering, and his research team, now have published a novel method for engineering human therapeutic...

MILFORD, Mass., Jan. 20, 2012 /PRNewswire/ -- Waters Corporation (WAT:NYSE) and Ireland's National Institute for Bioprocessing Research and Training (NIBRT) announced today the availability of the world's first database for glycan analysis by UltraPerformance Liquid Chromatography® (UPLC®). Developed by Professor Pauline Rudd's research team at NIBRT, the new GlycoBase 3+ Database is the first-of-its-kind repository of chromatographic retention positions expressed in...

SAN DIEGO, April 7, 2011 /PRNewswire/ -- Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule...